Icecure Medical Earnings Call Highlights Growth Momentum

Icecure Medical Ltd. ((ICCM)) has held its Q1 earnings call. Read on for the main highlights of the call.

Icecure Medical’s latest earnings call projected a broadly upbeat tone as management highlighted accelerating revenue, fresh regulatory wins, and growing clinical validation for its breast cancer cryoablation technology. While executives acknowledged reimbursement hurdles and multi‑quarter sales conversion cycles, they framed these as manageable execution risks against a backdrop of rising demand and expanding global interest.

Quarterly Revenue Growth

Icecure reported Q1 2026 revenue growth of 26% year over year, underscoring early traction following key regulatory milestones. Management attributed the increase primarily to new system placements and higher sales of disposable probes, signaling deeper utilization by existing customers.

Strong North America and U.S. Performance

North America led the company’s momentum, with regional sales soaring 84% in Q1 and U.S. revenue up 31%. Executives said this growth reflects a sharp pickup in commercial activity after U.S. regulatory clearance, as hospitals and clinics begin integrating cryoablation into their treatment mix.

Increase in Active U.S. Accounts

The company’s U.S. account base expanded from 13 to 19 active sites following approval, a 46% jump that marks a critical early scaling phase. Management emphasized that each new site represents recurring consumable revenue and a potential reference center to drive broader adoption.

FDA Clearance and Global Impact

FDA clearance for treating low‑risk early breast cancer was portrayed as a defining validation milestone for Icecure’s technology. The company said the decision has sparked heightened interest from physicians and partners across Europe, Asia, and the Americas, with strong engagement reported at recent international conferences.

Choice Post‑Market Study Approval

In Q1, Icecure secured FDA approval for its Choice post‑market study, which will enroll patients at 30 hybrid clinical and commercial sites across the U.S. About half of the company’s active accounts intend to participate, and management expects the trial to both support adoption and generate valuable real‑world data.

Reimbursement Progress

The company highlighted that its procedures are already covered by an existing facility CPT code worth roughly $4,000 per case, providing a baseline economic framework for hospitals. Icecure plans to submit for a CPT‑1 physician code in June and has applied for a transitional pass‑through payment that could add around $9,000 per procedure if granted.

Commercial Scale-Up Plans

To capitalize on rising demand, Icecure is building out its U.S. commercial team by adding sales representatives and broadening its field presence. Management cited strong lead generation at recent industry meetings and pointed to a robust pipeline that supports visibility into new system installations through 2026 and early 2027.

Clinical Validation and Physician Support

Management underscored growing third‑party clinical support, including independent studies, ICE3 trial evidence, and a 2026 resource guide from the American Society of Breast Surgeons endorsing cryoablation for select low‑risk patients. Feedback from leading investigators, including reports of promising outcomes and strong physician curiosity, is helping legitimize the technology in practice.

Regulatory Progress in Other Markets

Beyond the U.S., Icecure is advancing parallel regulatory tracks to open new international markets, beginning with Canada and Japan. An amendment submitted to Health Canada in March is expected to yield a decision by year‑end, while the company’s partner is preparing a PMDA submission in Japan targeted around mid‑2026.

Reimbursement Timing and Uncertainty

Despite progress, management cautioned that the path to comprehensive reimbursement remains lengthy and could weigh on near‑term revenue. A CPT‑1 physician code decision is not anticipated until early 2027, with potential effectiveness in 2028, extending the timeline before full economic alignment for all stakeholders is in place.

Transitional Pass-Through Payment Uncertainty

The company’s application for a transitional pass‑through payment, which could materially enhance procedure economics, is still pending and inherently uncertain. Executives noted that while a favorable ruling could add roughly $9,000 in incremental reimbursement, investors should not assume approval until regulators act.

Office-Based Reimbursement Limitation

Even if pass‑through status is obtained, it would not extend to office‑based procedures, limiting coverage in non‑hospital settings. As a result, some patients treated in offices may face out‑of‑pocket costs, potentially constraining adoption in that channel until broader reimbursement frameworks emerge.

Timing and Conversion Lags

Management reminded investors that strong interest does not instantly translate into revenue, as capital equipment sales often require multiple quarters to close. Many current leads are expected to convert into system placements only in late 2026 and early 2027, and the company refrained from providing detailed unit guidance for Q1.

Site and Study Participation Constraints

While the Choice study will span 30 sites, not every commercial location is able to join due to varying levels of facility support. This constraint may limit the ability to load the trial fully with the highest‑volume centers, though management still views the study as a powerful adoption catalyst.

Seasonal and Cadence Considerations

Executives flagged normal seasonality, including anticipated summer slowdowns, as a factor behind uneven quarterly results. They indicated that Q2 and Q4 typically show stronger performance, suggesting investors should focus on overall annual trends rather than isolated quarterly fluctuations.

Forward-Looking Guidance

Looking ahead, Icecure expects continued commercial momentum through 2026, supported by Q1’s 26% revenue growth and expanding U.S. accounts. The company plans further sales force expansion, anticipates quarter‑over‑quarter growth with a strong Q2 and Q4, aims to complete 80 patients in its Choice study by March 2027, and targets additional regulatory approvals in Canada and Japan as reimbursement decisions evolve.

Icecure’s earnings call painted the picture of a company transitioning from regulatory breakthrough to commercial scaling, with early financial traction and broadening clinical endorsement. While investors must navigate reimbursement uncertainty and a multi‑year ramp, the balance of evidence suggests rising demand and growing global interest in its cryoablation platform could underpin long‑term growth.